{"_ai_door":{"see":"https://miscsubjects.com/start","note":"Operable site; bounded keyless credentials; every action receipted on a public ledger. Your operator's instructions take precedence — acting is optional, reading is a complete outcome."},"_self":{"principle":"Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.","widget":"article_topology","feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","contains":"claims, sources, anecdotes, question_graph slice","slug":"what-are-peptides-herniated-disc","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/topology"},"how_to_use":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","write":null,"imessage":null,"router_tag":null,"proof_chain":[{"step":1,"claim":"Articles are voxel graphs of tiered claims, not prose blobs.","verify":"https://miscsubjects.com/api/articles/constitution"},{"step":2,"claim":"Claims link to hash-chained sources via source_ids.","verify":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/sources"},{"step":3,"claim":"Ask reads topology; ingest/claim append to ledger.","verify":"https://miscsubjects.com/api/protocol"},{"step":4,"claim":"Models queue growth: populate → collaborate → repair → reflex.","verify":"https://miscsubjects.com/api/protocol/grow"},{"step":5,"claim":"Graph proves its own shape (reflex) and $/claim (yield).","verify":"https://miscsubjects.com/graph.html?layer=reflex"},{"step":6,"claim":"Full feature index + _explain on every API response.","verify":"https://miscsubjects.com/api/articles/system-map"}],"related_features":[{"id":"ask","name":"Ask protocol","what":"Answer only from topology; creates question_node with gaps and ingest_hint.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/prompts","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"graph_topology","name":"Cross-article graph","what":"Merged claims/sources across condition+stack slugs for one question.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/graph-topology?question=..."}},{"id":"question_graph","name":"Question graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output).","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/question-graph","write":"https://miscsubjects.com/api/protocol/ask"}},{"id":"voxels","name":"Voxel graph","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance.","urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/voxels","write":"https://miscsubjects.com/api/protocol/claim"}}],"system_map":"https://miscsubjects.com/api/articles/system-map","system_map_markdown":"https://miscsubjects.com/api/articles/system-map?format=markdown","not_medical_advice":true},"_explain":{"feature":"topology","name":"Article topology","what":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","why":"Every feature is auditable collective intelligence","how":"Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER.","model":null,"verifies":null,"urls":{"read":"https://miscsubjects.com/api/articles/what-are-peptides-herniated-disc/topology"},"imessage":null,"router":null,"related":[{"id":"ask","what":"Answer only from topology; creates question_node with gaps and ingest_hint."},{"id":"graph_topology","what":"Merged claims/sources across condition+stack slugs for one question."},{"id":"question_graph","what":"Ask nodes (questions + gaps) and evidence_ingest nodes (pasted model output)."},{"id":"voxels","what":"Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance."}],"not_medical_advice":true},"slug":"what-are-peptides-herniated-disc","title":"Peptides for a herniated disc: BPC-157, TB-500 and ARA-290 measured against a 70% spontaneous resorption rate","register":"source_ledger","tags":["peptide","matrix"],"updated_at":"2026-08-04T20:38:24.950Z","body_excerpt":"A herniated disc is a tear in the tough outer ring of a spinal disc through which the soft inner core pushes out and presses on, or chemically irritates, a nerve root. BPC-157, TB-500 and ARA-290 are three synthetic peptides sold in the United States for laboratory research only, and they are routinely proposed together — as a \"stack\" — for exactly that problem.\n\nThe proposal rests on a decomposition. A herniated disc is not one disease process; it is at least four, and the three peptides are pointed at three different ones. Whether that decomposition survives contact with the evidence is the whole question, and the answer differs sharply by layer.\n\n## Seven in ten herniations shrink without anyone doing anything\n\nA 2024 meta-analysis pooled 31 studies and 2,233 patients treated conservatively for lumbar disc herniation. The overall rate of spontaneous resorption was 70.39%. Broken out by herniation type: 87.77% for sequestration, 66.91% for extrusion, 37.53% for protrusion, 13.33% for a bulge. Most of it happened inside six months.\n\n[[embed:source:s20]]\n\nAn earlier meta-analysis of 11 cohort studies put the pooled figure at 66.66%.\n\n[[embed:source:s21]]\n\nTwo independent pools, seven years apart, landed within four percentage points of each other. That is the number every claim below has to be read against. If a compound is taken for twelve weeks and the leg pain resolves, the base rate says that is the most likely outcome anyway — and the bigger the herniation, the more likely it resorbs, because extruded and sequestered fragments are the ones that disappear most reliably.\n\nThe trial record says the same thing from a different direction. In a randomised trial of 283 patients with six to twelve weeks of severe sciatica, 95% of patients in both arms — early microdiscectomy and prolonged conservative care — reported recovery at one year. Surgery got them there faster. It did not get more of them there.\n\n[[embed:source:s22]]\n\n## Disc bulges are common in people who feel nothing at all\n\nA systematic review of imaging in 3,110 asymptomatic people found disc protrusions in 29% of 20-year-olds and 43% of 80-year-olds, and disc degeneration in 37% and 96% respectively.\n\n[[embed:source:s30]]\n\nTwo things follow. An MRI finding is not by itself the cause of a patient's pain. And a follow-up MRI showing a smaller herniation is not proof that anything was treated, because the herniation may never have been the pain generator and would probably have shrunk regardless.\n\n## A herniated disc is four problems wearing one name\n\n**Layer 1 — mechanical.** A displaced fragment of nucleus pulposus occupies space it should not, and deforms a nerve root. A geometry problem.\n\n**Layer 2 — inflammatory.** Nucleus pulposus is immunologically sequestered inside a healthy disc. Once it leaks out it behaves as foreign tissue: macrophages arrive, TNF-α and other cytokines rise, and the nerve root becomes chemically irritated. This layer is why some people with tiny herniations are in agony and some with enormous ones barely notice.\n\n[[embed:source:s35]]\n\n**Layer 3 — neural.** Sustained compression and sustained chemical exposure damage the nerve fibres themselves. Numbness, burning and weakness that persist after the mechanical problem resolves belong here.\n\n**Layer 4 — structural.** The annular tear, the surrounding ligament and muscle, and the disc's own matrix are damaged tissue in a near-avascular structure that heals slowly.\n\nThe stack argument runs: layers 2, 3 and 4 have separate biology, no existing conservative treatment addresses layer 4 at all, and three peptides with three different mechanisms can therefore be combined without redundancy. Layer 1 is conceded to surgery or to time.\n\n## The layer-to-compound matrix\n\n| Layer | What is actually happening | Proposed compound | Strongest evidence class | Grade | What would falsify it |\n|---|---|---|---|---|---|\n| Mechanical | Displaced nucleus pulposus deforming a nerve root | None | Not applicable — no","ranking":"safety-first (interaction_risk/limitations), then quote-gated effective_weight","claims":[{"id":"c23","text":"Pooled across trials, a steroid injection around the spine takes 6.2 points off leg pain on a 0-to-100 scale in the short term, and nothing that can be told apart from chance in the long term. Every proposed threshold for a change a person would actually notice sits between 10 and 30 points, so 6.2 falls below all of them.","tier":"human","section":"The standard options buy speed, and they are not cheap","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s23","s42"],"why_material":"The closest established analogue to what the peptide stack proposes produces an effect smaller than patients can reliably notice.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c24","text":"SPORT, the big American trial, measured surgery as costing 14,137 dollars more than non-surgical care over two years, working out at 34,355 to 69,403 dollars for each year of good-quality life gained. That money buys relief sooner, not a better chance of ending up recovered.","tier":"human","section":"The standard options buy speed, and they are not cheap","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s31"],"why_material":"Prices the only option that addresses the mechanical layer, so the peptide spend can be compared against a real alternative.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c36","text":"In the United States the cash price of that steroid injection commonly runs between 800 and 5,000 dollars, against a Medicare allowable of about 161 dollars for the same procedure.","tier":"human","section":"The standard options buy speed, and they are not cheap","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s23","s42"],"why_material":"What a person is charged for the standard option is part of deciding whether to take it.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c21","text":"32 rats had the Achilles tendon cut and repaired, then four weeks of daily injections into the belly: nothing, BPC-157 at 10 micrograms per kilogram a day, TB-500 at 60 micrograms per kilogram a day, or both together. TB-500 on its own was the only arm to beat the control on how much load the tendon took before it failed. The two together beat neither one alone, which the authors read as a sign that both end up pulling the same levers inside the cell.","tier":"preclinical","section":"Put the two together and nothing extra happened","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s27"],"why_material":"A direct hit on the stack rationale delivered by the only experiment that has tested the pair in any tissue.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c25","text":"US regulators put BPC-157, and the thymosin beta-4 fragment LKKTETQ sold as TB-500, in Category 2 of their record of bulk drug substances. They flagged both for the risk that the immune system reacts to them, for leftover impurities from making them, and for being hard to pin down chemically. On TB-500 the FDA states outright that it has found no data at all on what happens when a person is exposed to it.","tier":"mechanistic","section":"In US law none of this is a medicine","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s32"],"why_material":"Establishes that every US supply channel for all three sits outside pharmaceutical manufacturing controls.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c37","text":"Neither BPC-157 nor TB-500 appears on the 503A or 503B lists, so no compounding pharmacy in the United States can lawfully make either of them. ARA-290 was never approved and cannot be bought commercially at all.","tier":"mechanistic","section":"In US law none of this is a medicine","slot":"limitations","interaction_risk":false,"status":"active","source_ids":["s32"],"why_material":"Anything a person obtains is coming from outside the legal supply chain, with no one accountable for what is in the vial.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c28","text":"The cheapest of the four is a rat study. Give the rats a herniated disc by implanting a piece of the soft centre of their own disc, then treat them with BPC-157, with TB-500, with both, or with nothing, and measure how easily pain is provoked and how much of the herniation is left.","tier":"speculative","section":"Four experiments would settle this, cheapest first","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"source_status":"Prospective research design proposed in-page; no source exists because none of these experiments has been run.","why_material":"Each empty cell in the matrix names the specific experiment that would fill it, which makes the gaps falsifiable rather than rhetorical.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.12,"quote_gated":false},{"id":"c38","text":"A step dearer, someone could run a study in any spinal tissue that tests several doses of either peptide against each other and shows whether more of it does more. No such study exists, which is why no dose for the spine can be defended.","tier":"speculative","section":"Four experiments would settle this, cheapest first","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"source_status":"Prospective research design proposed in-page; no source exists because none of these experiments has been run.","why_material":"Without a dose-response curve there is no rational basis for any spinal dose anyone recommends.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.12,"quote_gated":false},{"id":"c39","text":"Dearer again would be a trial in people with a pinched nerve root, allocated at random, with the scans read by someone who does not know who got what, and big enough to beat a comparison group in which 66 to 70 percent recover on their own.","tier":"speculative","section":"Four experiments would settle this, cheapest first","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"source_status":"Prospective research design proposed in-page; no source exists because none of these experiments has been run.","why_material":"Names the specific design that would have to beat the natural recovery rate before any claim of benefit could stand.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.12,"quote_gated":false},{"id":"c40","text":"The most expensive of the four would be a trial of ARA-290 in people whose nerve root is being compressed, since none of its human evidence covers that situation.","tier":"speculative","section":"Four experiments would settle this, cheapest first","slot":"limitations","interaction_risk":false,"status":"active","source_ids":[],"source_status":"Prospective research design proposed in-page; no source exists because none of these experiments has been run.","why_material":"The one compound with human data has never been tested in the injury this article is about.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.12,"quote_gated":false},{"id":"c1","text":"ARA-290 is the only one of the three that has been through randomised Phase II trials in people. In those trials, run in patients with sarcoidosis, it lowered nerve pain and grew nerve fibres back in the cornea, the clear front of the eye.","tier":"human","weight":0.8,"section":"One of the three has human trials, the other two have rats and dishes","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s13","s17"],"source_status":"sourced","why_material":"Provides the only human clinical data among the peptides for nerve-related symptoms relevant to disc herniation.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c3","text":"No study in people has shown BPC-157 repairing a herniated disc. Nearly everything known about it comes from animals and from cells in a dish.","tier":"human","weight":0.8,"section":"One of the three has human trials, the other two have rats and dishes","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s5","s9","s11"],"source_status":"sourced","why_material":"Establishes the evidence gap for the primary condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c6","text":"A 2024 review pooled 31 studies and 2,233 people who were treated without surgery. In 70.39% of them the herniation shrank away on its own, most of it inside six months.","tier":"human","section":"Seven in ten herniations shrink away without anyone doing anything","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s20"],"why_material":"This is the base rate every efficacy claim on the page must be read against.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c7","text":"An earlier review of 11 studies put the same figure at 66.66%. That team and the 2024 team, working seven years apart, landed within four percentage points of each other.","tier":"human","section":"Seven in ten herniations shrink away without anyone doing anything","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s21"],"why_material":"Two independent pools agreeing makes the base rate robust rather than a single-study artefact.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c8","text":"283 people with severe sciatica that had already lasted six to twelve weeks were split at random. Half had the disc operated on early, half carried on with ordinary care. At one year, 95% of each group said they had recovered. Surgery got people there faster. It did not get more of them there.","tier":"human","section":"Surgery got people better sooner, not more often","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s22"],"why_material":"Establishes that speed, not eventual outcome, is what any intervention in this window is competing on.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c9","text":"Scans of 3,110 people with no back symptoms at all found a disc pushed out of place in 29% of the 20-year-olds and 43% of the 80-year-olds. Discs showing wear turned up in 37% of the 20-year-olds and 96% of the 80-year-olds.","tier":"human","section":"Scans find worn and displaced discs in people whose backs do not hurt","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s30"],"why_material":"An MRI finding is not by itself the pain generator, so a follow-up MRI showing shrinkage is not proof that anything was treated.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c12","text":"The FIRST II trial took 40 people whose herniated disc was confirmed on a scan and whose sciatica was bad enough that surgery was already on the table. At random, each got either a single drip of the anti-inflammatory drug infliximab at 5 mg per kilogram or a dummy drip. Both groups improved a lot. Neither beat the other, and seven people in each group went on to have the operation anyway.","tier":"human","section":"The chemistry hurts more than the squeeze","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s24"],"why_material":"The most potent available TNF-alpha blockade produced no separation from placebo in the target condition.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c13","text":"84 adults with a pinched nerve root in the lower back were given one of three injections into the space around the spine: a steroid, the anti-inflammatory drug etanercept, or plain salt water. The steroid beat salt water on leg pain by 1.26 points, a gap small enough that chance could account for it. Etanercept did worse than the steroid on how well people could function, and that gap was too big for chance to account for.","tier":"human","section":"The chemistry hurts more than the squeeze","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s25"],"why_material":"Targeted TNF blockade underperformed steroid on function, which caps the inflammatory argument.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c14","text":"A separate trial injected etanercept right next to the nerve root in 49 people, at three different doses. Only the smallest dose, 0.5 mg, pulled away from placebo. The 2.5 mg and 12.5 mg doses did not, and even the one result that pulled away did so against a loose statistical bar (P < 0.1).","tier":"human","section":"The chemistry hurts more than the squeeze","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s26"],"why_material":"An inverse dose-response at a loose threshold is weak evidence, and it is the strongest positive result the inflammatory hypothesis has.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c16","text":"A Phase 2 pilot trial split 22 people who had sarcoidosis and damage to their small nerve fibres into two groups, for four weeks: ARA-290 into a vein, or a dummy drip. The ARA-290 group improved more on the standard checklist of small-fibre symptoms. On how much pain people felt, both groups improved about the same.","tier":"human","section":"Of the four problems, only the nerve damage has human trials behind it","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s29"],"why_material":"The symptom endpoint separated and the pain endpoint did not, which is the pattern across the ARA-290 record.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c17","text":"A larger Phase 2b trial gave 64 people one of three doses of ARA-290, or a dummy, for 28 days. The main thing measured was how much nerve fibre had grown back in the cornea, the clear front of the eye. The 4 mg group gained 697 square micrometres of it over placebo (95% CI 159 to 1,236; P = 0.012), and newly growing nerve fibres in the skin, the ones carrying the GAP-43 marker, increased in that same group.","tier":"human","section":"Of the four problems, only the nerve damage has human trials behind it","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s28","s34"],"why_material":"A measured structural regeneration endpoint met, with the pain endpoint missed — the strongest and the most honest result on the page.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c18","text":"Every human result for ARA-290 comes from people whose small nerve fibres were damaged by a disease or by inflammation. None of it comes from a nerve root being squashed by a disc. That is a different injury, with a different cause, and one that already has a fix.","tier":"human","section":"Of the four problems, only the nerve damage has human trials behind it","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s28","s29","s34"],"why_material":"Names the disease boundary the stack argument has to cross and has not.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c22","text":"Searching PubMed and ClinicalTrials.gov turns up no finished trial and no running trial of BPC-157, TB-500 or ARA-290 in a herniated disc, in a pinched nerve root, or in disc repair, in people or in animals. Outside the rat Achilles study, no trial has tested any two of them together.","tier":"human","section":"Search the trial registries and nothing comes back","slot":"what_is_unknown","interaction_risk":false,"status":"active","source_ids":["s33","s34"],"why_material":"The three-compound stack for a herniated disc has never been the subject of an experiment of any kind.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c27","text":"For a disc squeezed out at L5/S1, 66.91% shrink away on their own inside roughly six months, and 95% of people say they have recovered within a year on ordinary care. Against those odds, one person feeling better at twelve weeks tells you almost nothing about whether the treatment was what did it.","tier":"human","section":"Why one person getting better at twelve weeks settles nothing","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s20","s22"],"why_material":"This is why the page refuses to treat persuasive individual outcomes as evidence, and the arithmetic is stated so it can be checked.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c29","text":"How far the disc material had travelled changed the odds sharply in that same pool. 87.77% of the pieces that had broken off completely disappeared, against 66.91% of the ones squeezed out through a tear, 37.53% of the discs merely pushing outwards, and 13.33% of plain bulges.","tier":"human","section":"Seven in ten herniations shrink away without anyone doing anything","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s20"],"why_material":"The odds of the problem resolving without treatment depend heavily on which kind of herniation a person has.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c35","text":"In that same 64-person trial, the nerve fibres grew back but the pain did not follow. Once placebo was subtracted, the pain improvement in the 4 mg group could not be told apart from chance (P = 0.157).","tier":"human","section":"Of the four problems, only the nerve damage has human trials behind it","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s28","s34"],"why_material":"Nerve regrowth and pain relief came apart in the same trial, which is the honest limit of the ARA-290 evidence.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.8,"quote_gated":false},{"id":"c2","text":"In rats whose spinal cords were crushed, the ones given BPC-157 got more movement back than the ones that were not.","tier":"preclinical","weight":0.5,"section":"One of the three has human trials, the other two have rats and dishes","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s6"],"source_status":"sourced","why_material":"Direct animal evidence for spinal injury repair pathway.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c4","text":"In human disc cells kept alive in a dish, TB-500 cut the number of cells that killed themselves off.","tier":"preclinical","weight":0.5,"section":"One of the three has human trials, the other two have rats and dishes","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s0"],"source_status":"sourced","why_material":"Relevant in vitro data on disc cells.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c15","text":"In animals, blocking the inflammatory signal TNF with an injection around the spine shortens how long the nerve stays painfully oversensitive. So the idea holds up. It is the trials in people that did not deliver it.","tier":"preclinical","section":"The chemistry hurts more than the squeeze","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"Separates a real mechanism from a treatment target that works, which is the distinction the page is built on.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c19","text":"The spine result cited most often for BPC-157 is a rat study. The tail end of the spinal cord was crushed for 60 seconds, then a single injection went into the belly. Those rats moved better afterwards, lost fewer of the nerve cells that drive muscle, and kept more of the insulating sheath around their nerves. They were followed for 360 days.","tier":"preclinical","section":"The structural case for BPC-157 rests on rats","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s6"],"why_material":"The strongest BPC-157 result in nervous tissue, and it is a cord compression model rather than a disc.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.5,"quote_gated":false},{"id":"c10","text":"A herniated disc sounds like one thing and is really four, happening at once: something pressing on the nerve, chemistry inflaming it, damage to the nerve itself, and a tear in a part of the body that mends badly. Anything offered as a fix only ever addresses some of the four.","tier":"mechanistic","section":"A herniated disc is four problems wearing one name","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"The stack argument depends entirely on these four layers having separate biology; the decomposition is the load-bearing premise.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c11","text":"Nobody, including the people selling these compounds, claims that a peptide can push a displaced piece of disc back where it came from. There is no proposed mechanism by which one would.","tier":"mechanistic","section":"No peptide moves a displaced piece of disc","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s20"],"why_material":"Marks the boundary of the honest claim, and any vendor asserting a peptide puts the disc back is making a claim with no mechanism behind it.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c30","text":"The first of the four is pressure. The soft centre of the disc has pushed out of place and is pressing on a nerve root.","tier":"mechanistic","section":"A herniated disc is four problems wearing one name","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"Naming each of the four problems separately is what lets a reader see which ones any given treatment could touch.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c31","text":"The second is chemistry. The soft centre of the disc is normally sealed away from the immune system and never meets it, so when it leaks out the body reacts to it as something foreign and the nerve root becomes inflamed.","tier":"mechanistic","section":"A herniated disc is four problems wearing one name","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"The inflammatory part of the injury is the part that anti-inflammatory drugs and peptides are aimed at.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c32","text":"The third is damage to the nerve itself. Being squeezed for weeks and bathed in inflammatory chemicals injures the nerve fibres, and that injury can outlast whatever caused it.","tier":"mechanistic","section":"A herniated disc is four problems wearing one name","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"Explains why pain can persist after the herniation itself has gone.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c33","text":"The fourth is the tear itself, in the tough outer ring of the disc and the scaffolding around it. That tissue has almost no blood supply, which is why it mends slowly and badly.","tier":"mechanistic","section":"A herniated disc is four problems wearing one name","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s35"],"why_material":"The structural repair problem is the one with the worst natural healing and the least evidence behind any intervention.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c34","text":"The body clears a loose piece of disc slowly, over months. Scavenger cells eat it, new blood vessels grow into it, and it dries out. A surgeon takes the same piece out in about an hour.","tier":"mechanistic","section":"No peptide moves a displaced piece of disc","slot":"what_it_is","interaction_risk":false,"status":"active","source_ids":["s20"],"why_material":"Sets the two real routes by which displaced disc material actually goes away, neither of which is a peptide.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c26","text":"The accounts from people who say these compounds helped describe pain easing over two to six weeks. That is also how long inflammation takes to settle by itself, and not one of the accounts involved a blinded comparison. One of the writers says so himself. The accounts from people who say nothing happened come from people who used the same compounds at similar doses, over and over, and felt no difference.","tier":"anecdotal","section":"The people who say it worked, and the people who say it did nothing","slot":"who_claims_what","interaction_risk":false,"status":"active","source_ids":["s36","s37","s38","s39","s40","s41"],"why_material":"Both patterns are single-person observations without controls, and the page labels them as such rather than as weak evidence.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.3,"quote_gated":false},{"id":"c5","text":"Only two published studies have put TB-500 anywhere near a spinal disc, and both were done in a dish rather than in a living body.","tier":"preclinical","weight":0.5,"section":"One of the three has human trials, the other two have rats and dishes","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s4"],"source_status":"sourced","why_material":"Quantifies the thin evidence base for disc applications.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true},{"id":"c20","text":"Neither BPC-157 nor TB-500 has ever been given to an animal with a deliberately herniated disc and compared against an untreated one. Nobody has measured whether the disc shrank away faster, whether the tough outer ring of the disc held together, whether the disc kept its height, or whether the animal behaved as though it were in less pain.","tier":"preclinical","section":"The structural case for BPC-157 rests on rats","slot":"what_is_known","interaction_risk":false,"status":"active","source_ids":["s4"],"why_material":"The cheapest experiment that would test the structural claim has never been run, which is a named gap rather than a hedge.","retracted_at":null,"retraction_reason":null,"challenged_by":[],"effective_weight":0.22,"quote_gated":true}],"sources":[{"id":"s5","type":"other","url":"https://friscorehab.com/can-bpc-157-heal-a-herniated-disc-what-patients-with-back-pain-should-know/","title":"Can BPC-157 Heal a Herniated Disc?","quote":"There is currently no strong clinical evidence showing BPC-157 can repair a herniated disc in humans.","summary":"Clinic article summarizing lack of human evidence for BPC-157 in disc herniation.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"9e3c28ff47e8f5f3a3302c5bb47be4399cf3bea60ef015f989e7f18539eab1db"},{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31266512/","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","quote":"BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","summary":"2019 rat study on BPC-157 post-spinal cord compression injury.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"89c034e001bf4b453c986f202afc5ea351f9cb0a721902765a5c79d5e63a12fe"},{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2886502/","title":"Exogenous thymosin β4 prevents apoptosis in human intervertebral disc cells","quote":"A significant reduction in disc cell apoptosis occurred after TB4 treatment.","summary":"2009 in vitro study on thymosin beta-4 in human disc cells.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"b9e1f04ff1449dd3ea9067c663140803472dc42eedf03af096da737093c45da6"},{"id":"s4","type":"pubmed","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"Spine/intervertebral disk studies were limited to in vitro work","summary":"2026 review mapping TB-500 literature; notes sparse disc data.","claim_ids":["c5"],"link_status":"http_403","quote_status":"unverified","hash":"86a0926e4ccaaba558c57fc3fa2606fdb0af356f5abb0192c3e94b4d6277f1a2"},{"id":"s13","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/","title":"ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss","quote":"ARA 290 is a small peptide engineered to activate the innate repair receptor","summary":"2013 Phase II trial results for ARA-290 in sarcoidosis neuropathy.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"a3c50b65c5571af684771cbaec4ef646d9578e864f3ca855c1929b943332a4b0"},{"id":"s17","type":"other","url":"https://bamapain.com/sciatica/","title":"Leg Pain & Sciatica Treatment","quote":"Phase II data showing increased corneal nerve fiber density and reduced neuropathic symptoms","summary":"Clinic page summarizing ARA-290 Phase II neuropathy trials.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"a6dd613f4622b122d3d37c62f3b1587defcb6e6ba06aa47937a78d70259a0a6e"},{"id":"s9","type":"other","url":"https://www.instagram.com/reel/DXPt0URAecD/","title":"Instagram reel on BPC-157","quote":"there are zero human clinical trials showing BPC-157 regenerates intervertebral disc tissue. Zero.","summary":"Spine specialist stating absence of human disc regeneration trials.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"a3a0d22557ab35f39648854d8b40360ed9b20e81dff0ccd6a101aa53b3c50ab8"},{"id":"s11","type":"other","url":"https://medisearch.io/blog/can-bpc-157-help-with-a-herniated-disk","title":"Can BPC-157 Help With A Herniated Disc?","quote":"According to available scientific evidence, BPC157 supplements cannot help with herniated discs.","summary":"Article concluding lack of evidence for BPC-157 in disc herniation.","claim_ids":["c3"],"link_status":"ok","quote_status":"verified","hash":"97fc6ecd5114bcb5d79435c9c7d09f350a57611eb207e0072e016f9fd2104b74"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37559207/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis (Clin Spine Surg, 2024; PMID 37559207)","quote":"Thirty-one studies with 2233 patients who received conservative treatment were included for this analysis. We found that the pooled overall incidence of disk resorption was 70.39%, 87.77% for disk sequestration, 66.91% for disk extrusion, 37.53% for disk protrusion, and 13.33% for disk bugle, respectively. The resorption process mainly occurred within 6 months of conservative treatment.","claim_ids":[],"hash":"502b9fbd2bf861229e5b649972796cb32bc516120482d3328792fe843457483f"},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28072796/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis (Pain Physician, 2017; PMID 28072796)","quote":"Our results represent the pooled results from 11 cohort studies. The overall incidence of spontaneous resorption after LDH was 66.66% (95% CI 51% - 69%).","claim_ids":[],"hash":"49da38253a4bb3aef3097395b1fd72080a9e871debac558cd60770fc6310d3bb"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17538084/","title":"Surgery versus prolonged conservative treatment for sciatica (N Engl J Med, 2007; PMID 17538084)","quote":"There was no significant overall difference in disability scores during the first year (P=0.13). Relief of leg pain was faster for patients assigned to early surgery (P<0.001). In both groups, however, the probability of perceived recovery after 1 year of follow-up was 95%.","claim_ids":[],"hash":"b323ee1d47b5e0916261daa72133792d01a83a5e4b31ccfc61e834168cb18dee"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23362516/","title":"Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis (Ann Intern Med, 2012; PMID 23362516)","quote":"The pooled results showed a significant, although small, effect of epidural corticosteroid injections compared with placebo for leg pain in the short term (mean difference, -6.2 [95% CI, -9.4 to -3.0]) and also for disability in the short term (mean difference, -3.1 [CI, -5.0 to -1.2]). The long-term pooled effects were smaller and not statistically significant.","claim_ids":[],"hash":"602eb960ca61ac3d1cf746ecba7af773e3e33478789a63ef745555fb2dc57d92"},{"id":"s24","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16371894/","title":"The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study (Spine, 2005; PMID 16371894)","quote":"Forty patients were allocated to a single intravenous infusion of either infliximab 5 mg/kg or placebo. A significant reduction in leg pain was observed in both groups, with no significant difference between treatment regimens. Seven patients in each group required surgery.","claim_ids":[],"hash":"7b97ebab43e89d414cb7638f7e7ef767a02fbaa18b1e7a422a7f3d75c8beb8c3"},{"id":"s25","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22508732/","title":"Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial (Ann Intern Med, 2012; PMID 22508732)","quote":"The group that received epidural steroids had greater reductions in the primary outcome measure than those who received saline (mean difference, -1.26 [95% CI, -2.79 to 0.27]; P = 0.11) or etanercept (mean difference, -1.01 [CI, -2.60 to 0.58]; P = 0.21).","claim_ids":[],"hash":"a00d9be6293370fdc8ef57c1c2624c082eefd6637b80a46957b8933846c37982"},{"id":"s26","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/24165696/","title":"Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation (Spine, 2013; PMID 24165696)","quote":"Patients receiving 0.5-mg etanercept showed a clinically and statistically significant (P< 0.1) reduction in mean daily WLP compared with the placebo cohort from 2 to 26 weeks for both the per protocol population (-5.13 vs. -1.95; P= 0.066) and the intention-to-treat population (-4.40 vs. -1.84; P= 0.058).","claim_ids":[],"hash":"0faea4e3ffa31ae331eb290d552eb931b3cc34246d631c764239a32bb2f4ceba"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42542926/","title":"Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (Jt Dis Relat Surg, 2026; PMID 42542926)","quote":"Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone. The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation.","claim_ids":[],"hash":"f74201790a170127d18ab8e4d7a9070db456caf7af4acceb79d6b59acf6fa883"},{"id":"s28","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28475703/","title":"Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (IOVS, 2017; PMID 28475703)","quote":"The placebo-corrected mean change from baseline CNFA (um2) at day 28 was 109 (95% confidence interval [CI], -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively. Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group (P = 0.157).","claim_ids":[],"hash":"90dc1a0218b3019f29f6b6ab0d7e3c3a445e23bad7ea9dee7999b3f7e5c15d74"},{"id":"s29","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23168581/","title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (Mol Med, 2012; PMID 23168581)","quote":"A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial. The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo. The mean BPI and FAS scores improved significantly but equivalently in both patient groups.","claim_ids":[],"hash":"a0e8815fd61d935b0749fffab4e79d2bbb9c3db981870afecdac59d3e761c6c1"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25430861/","title":"Systematic literature review of imaging features of spinal degeneration in asymptomatic populations (AJNR, 2015; PMID 25430861)","quote":"Disk protrusion prevalence increased from 29% of those 20 years of age to 43% of those 80 years of age. Imaging findings of spine degeneration are present in high proportions of asymptomatic individuals, increasing with age.","claim_ids":[],"hash":"e73e4bc39d8be90cc4267bd894484e68b30b3db51a5331534b3fa2dde8a6e9ea"},{"id":"s31","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18777603/","title":"The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from SPORT (Spine, 2008; PMID 18777603)","quote":"Surgery was more costly than nonoperative care; the mean difference in total cost was $14,137 (95% CI: $11,737-16,770). The cost per QALY gained for surgery relative to nonoperative care was $69,403 (95% CI: $49,523-94,999) using general adult surgery costs and $34,355 (95% CI: $20,419-52,512) using Medicare population surgery costs.","claim_ids":[],"hash":"2b20ce8eac9d6ca0e2d5b95e17f1c9694c8dc60a493cfadafa91ae1f09579b6e"},{"id":"s32","type":"regulatory","url":"https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks","title":"FDA — Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (current as of 22 April 2026)","quote":"Compounded drugs containing BPC-157 may pose risk for immunogenicity for certain routes of administration and may have complexities with regard to peptide-related impurities and active pharmaceutical ingredient (API) characterization. FDA has identified no, or only limited, safety-related information for the proposed routes of administration.","claim_ids":[],"hash":"6f57835475459210f7c1a575819d22840c2e18ffd086791b2b2c8b1113511293"},{"id":"s33","type":"trial_registry","url":"https://clinicaltrials.gov/study/NCT07437547","title":"ClinicalTrials.gov NCT07437547 — BPC 157 for Acute Hamstring Muscle Strain Repair (Phase 2, recruiting)","quote":"BPC 157 for Acute Hamstring Muscle Strain Repair — Phase 2 — Recruiting.","claim_ids":[],"hash":"56aaa08a013763558f17094f20d200d5adcdb6a98e7dc437c0acc168d814b3e2"},{"id":"s34","type":"trial_registry","url":"https://clinicaltrials.gov/study/NCT02039687","title":"ClinicalTrials.gov NCT02039687 — Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms in Sarcoidosis (Phase 2, completed)","quote":"Study of Efficacy of ARA 290 on Corneal Nerve Fiber Density and Neuropathic Symptoms of Subjects With Sarcoidosis — Phase 2 — Completed.","claim_ids":[],"hash":"4acab3ad5e4300171ec122df1cfdf4c8bd3bcc36ca9c73416d210ac6428cc06f"},{"id":"s35","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29284846/","title":"Comparison of the Intravenous and Epidural Administration of TNF-alpha Antagonists in an Experimental Rat Pain Model (Anesth Essays Res, 2017; PMID 29284846)","quote":"Inflammatory cytokines secreted from the nucleus pulposus are thought to lead to lumbar nerve root compression-like symptoms. Tumor necrosis factor-alpha (TNF-a), an inflammatory cytokine, likely plays an important role in lumbar disc hernia-related leg pain.","claim_ids":[],"hash":"e82a7ec43c2632ea92af8925155a0f143097e30a220cb704246f2f1f95e3988e"},{"id":"s36","type":"x","url":"https://x.com/MuroCrypto/status/2083184469956059529","title":"@MuroCrypto on X, 31 July 2026 — six-week BPC-157 and TB-500 run with a herniated lumbar disc","quote":"My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks. Separate, normal doses like everyone recommends, injected into belly fat. After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better.","claim_ids":[],"hash":"4031f3abd749fee57c188d7280049a737fb12aa22dfcdb25ca4f8feba394c1f7"},{"id":"s37","type":"x","url":"https://x.com/AJA_Cortes/status/1794522474702336108","title":"@AJA_Cortes on X, 26 May 2024 — L5-S1 flare, oral BPC-157, seven days","quote":"Had a bad disc flare up this past weekend (I had a disc herniation at L5-S1 many years ago, never been the same since). Was staggering around in pain for a day and a half. Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo.","claim_ids":[],"hash":"14323c9a8b75908e0863dacdc74ab4504bc02d14380d11aed45e38ee82179b29"},{"id":"s38","type":"x","url":"https://x.com/prax1s_mm/status/2082901582627184835","title":"@prax1s_mm on X, 30 July 2026 — third failed peptide attempt for a joint problem","quote":"Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all.","claim_ids":[],"hash":"fb53bc8c76730a3a27f41e640f8a7a85b87fc32ad20e2318b31420853d147b83"},{"id":"s39","type":"x","url":"https://x.com/LtCrandog/status/2082758463407473109","title":"@LtCrandog on X, 30 July 2026 — ten years of BPC-157 use, no durable effect","quote":"Appreciate you acknowledging the potential placebo benefits. Been taking bpc157 off and on for over 10 years and really don't think it does much. Apart from not really healing anything I've had random tendinitis pop up even while being on bpc.","claim_ids":[],"hash":"accaaeeff34d9da3c3510f007226ad0f2455ad013f46d358b0781727028c3fd8"},{"id":"s40","type":"x","url":"https://x.com/UndergroundBio/status/2069216406814458355","title":"@UndergroundBio on X, 23 June 2026 — separating the inflammatory claim from the structural one","quote":"Hot take no one wants: BPC-157 is probably not fixing your herniated disc. What I actually think it might do is quiet the inflammatory fire that makes nerve pain so brutal. That's worth something, just not the miracle the forums promise.","claim_ids":[],"hash":"0fcfcd64a5284a749b27828f5aca76e933b5e43f4892a2852a991ee7463c2d42"},{"id":"s41","type":"x","url":"https://x.com/drmarlonperalta/status/2062565899714925044","title":"@drmarlonperalta on X, 4 June 2026 — pharmacist reporting durable relief after one cycle","quote":"3. BPC-157. I've suffered for 10+ years with lower back pain from a herniated disc. I would constantly reposition myself for relief while working. The nagging pain in the background limited how deeply I could focus. A 6-week cycle removed this distraction permanently.","claim_ids":[],"hash":"ef90b5abd5eaa04840d219a8f64eaf52cd4dd5518b51d0db9960984506ce4ede"},{"id":"s42","type":"other","url":"https://cost.sidecarhealth.com/n/epidural-steroid-injection-cost","title":"Sidecar Health — cost of an epidural steroid injection in the United States","quote":"Published US price range for a single epidural steroid injection, with the Medicare allowable near $161 and cash prices commonly running from several hundred to several thousand dollars depending on facility, imaging guidance and region.","claim_ids":[],"hash":"80acf6e58858248f976f0e99c16e4c2c160d838467d3304a5d4461ba54b1a369"},{"id":"s43","type":"other","url":"https://thepeptidecatalog.com/articles/bpc-157-buying-guide","title":"Where to Buy BPC-157: Price and Vendor Guide (2026)","quote":"Legitimate vendors with proper documentation typically charge $5-$8/mg. Since the FDA moved BPC-157 to the 503A Category 2 bulks list, compounding pharmacies can no longer produce it, and every legitimate source is now a research peptide vendor.","claim_ids":[],"hash":"7bb9093ec80fe93d3c08cd74ca2afcd0e0e8e4104e5784aa841fcbc2da11fc13"}],"anecdotal_sources":[{"id":"s36","type":"x","url":"https://x.com/MuroCrypto/status/2083184469956059529","title":"@MuroCrypto on X, 31 July 2026 — six-week BPC-157 and TB-500 run with a herniated lumbar disc","quote":"My lowest disc in the lower back is dried out, almost no fluid left, classic herniated disc. Flared up hard in March, could barely sit or stand without pain. Went on for 3 months with zero improvement. In June I ran BPC-157 and TB-500 for about 6 weeks. Separate, normal doses like everyone recommends, injected into belly fat. After 3-4 weeks it already felt better. Now after the cycle, zero pain in biceps and shoulder. Disc still needs physio and rest, but already much better.","claim_ids":[],"hash":"4031f3abd749fee57c188d7280049a737fb12aa22dfcdb25ca4f8feba394c1f7"},{"id":"s37","type":"x","url":"https://x.com/AJA_Cortes/status/1794522474702336108","title":"@AJA_Cortes on X, 26 May 2024 — L5-S1 flare, oral BPC-157, seven days","quote":"Had a bad disc flare up this past weekend (I had a disc herniation at L5-S1 many years ago, never been the same since). Was staggering around in pain for a day and a half. Decided to try to taking oral BPC157 at 2000mcg daily. Also got two deep tissue massages, and a chiro adjustment. 7 days later, pain free. Did the BPC157 help? Maybe, maybe not. Im always open to possibility of placebo.","claim_ids":[],"hash":"14323c9a8b75908e0863dacdc74ab4504bc02d14380d11aed45e38ee82179b29"},{"id":"s38","type":"x","url":"https://x.com/prax1s_mm/status/2082901582627184835","title":"@prax1s_mm on X, 30 July 2026 — third failed peptide attempt for a joint problem","quote":"Did 3mg of BCP & 5mg of TB500 daily for two weeks into my elbow. It didn't do jack shit. This is my 3rd time trying peptides for various joint/tendon stuff and my 3rd time not noticing any improvement at all.","claim_ids":[],"hash":"fb53bc8c76730a3a27f41e640f8a7a85b87fc32ad20e2318b31420853d147b83"},{"id":"s39","type":"x","url":"https://x.com/LtCrandog/status/2082758463407473109","title":"@LtCrandog on X, 30 July 2026 — ten years of BPC-157 use, no durable effect","quote":"Appreciate you acknowledging the potential placebo benefits. Been taking bpc157 off and on for over 10 years and really don't think it does much. Apart from not really healing anything I've had random tendinitis pop up even while being on bpc.","claim_ids":[],"hash":"accaaeeff34d9da3c3510f007226ad0f2455ad013f46d358b0781727028c3fd8"},{"id":"s40","type":"x","url":"https://x.com/UndergroundBio/status/2069216406814458355","title":"@UndergroundBio on X, 23 June 2026 — separating the inflammatory claim from the structural one","quote":"Hot take no one wants: BPC-157 is probably not fixing your herniated disc. What I actually think it might do is quiet the inflammatory fire that makes nerve pain so brutal. That's worth something, just not the miracle the forums promise.","claim_ids":[],"hash":"0fcfcd64a5284a749b27828f5aca76e933b5e43f4892a2852a991ee7463c2d42"},{"id":"s41","type":"x","url":"https://x.com/drmarlonperalta/status/2062565899714925044","title":"@drmarlonperalta on X, 4 June 2026 — pharmacist reporting durable relief after one cycle","quote":"3. BPC-157. I've suffered for 10+ years with lower back pain from a herniated disc. I would constantly reposition myself for relief while working. The nagging pain in the background limited how deeply I could focus. A 6-week cycle removed this distraction permanently.","claim_ids":[],"hash":"ef90b5abd5eaa04840d219a8f64eaf52cd4dd5518b51d0db9960984506ce4ede"}],"scientific_sources":[{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/31266512/","title":"Stable gastric pentadecapeptide BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","quote":"BPC 157 can improve the healing course of spinal cord injury and lead to functional recovery in rats","summary":"2019 rat study on BPC-157 post-spinal cord compression injury.","claim_ids":["c2"],"link_status":"ok","quote_status":"verified","hash":"89c034e001bf4b453c986f202afc5ea351f9cb0a721902765a5c79d5e63a12fe"},{"id":"s0","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2886502/","title":"Exogenous thymosin β4 prevents apoptosis in human intervertebral disc cells","quote":"A significant reduction in disc cell apoptosis occurred after TB4 treatment.","summary":"2009 in vitro study on thymosin beta-4 in human disc cells.","claim_ids":["c4"],"link_status":"ok","quote_status":"verified","hash":"b9e1f04ff1449dd3ea9067c663140803472dc42eedf03af096da737093c45da6"},{"id":"s4","type":"pubmed","url":"https://www.mdpi.com/2076-3417/16/12/6202","title":"Thymosin Beta-4 and TB-500 in Tissue Healing","quote":"Spine/intervertebral disk studies were limited to in vitro work","summary":"2026 review mapping TB-500 literature; notes sparse disc data.","claim_ids":["c5"],"link_status":"http_403","quote_status":"unverified","hash":"86a0926e4ccaaba558c57fc3fa2606fdb0af356f5abb0192c3e94b4d6277f1a2"},{"id":"s13","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3883966/","title":"ARA 290 Improves Symptoms in Patients with Sarcoidosis-Associated Small Nerve Fiber Loss","quote":"ARA 290 is a small peptide engineered to activate the innate repair receptor","summary":"2013 Phase II trial results for ARA-290 in sarcoidosis neuropathy.","claim_ids":["c1"],"link_status":"ok","quote_status":"verified","hash":"a3c50b65c5571af684771cbaec4ef646d9578e864f3ca855c1929b943332a4b0"},{"id":"s20","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/37559207/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-analysis (Clin Spine Surg, 2024; PMID 37559207)","quote":"Thirty-one studies with 2233 patients who received conservative treatment were included for this analysis. We found that the pooled overall incidence of disk resorption was 70.39%, 87.77% for disk sequestration, 66.91% for disk extrusion, 37.53% for disk protrusion, and 13.33% for disk bugle, respectively. The resorption process mainly occurred within 6 months of conservative treatment.","claim_ids":[],"hash":"502b9fbd2bf861229e5b649972796cb32bc516120482d3328792fe843457483f"},{"id":"s21","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28072796/","title":"Incidence of Spontaneous Resorption of Lumbar Disc Herniation: A Meta-Analysis (Pain Physician, 2017; PMID 28072796)","quote":"Our results represent the pooled results from 11 cohort studies. The overall incidence of spontaneous resorption after LDH was 66.66% (95% CI 51% - 69%).","claim_ids":[],"hash":"49da38253a4bb3aef3097395b1fd72080a9e871debac558cd60770fc6310d3bb"},{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/17538084/","title":"Surgery versus prolonged conservative treatment for sciatica (N Engl J Med, 2007; PMID 17538084)","quote":"There was no significant overall difference in disability scores during the first year (P=0.13). Relief of leg pain was faster for patients assigned to early surgery (P<0.001). In both groups, however, the probability of perceived recovery after 1 year of follow-up was 95%.","claim_ids":[],"hash":"b323ee1d47b5e0916261daa72133792d01a83a5e4b31ccfc61e834168cb18dee"},{"id":"s23","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23362516/","title":"Epidural corticosteroid injections in the management of sciatica: a systematic review and meta-analysis (Ann Intern Med, 2012; PMID 23362516)","quote":"The pooled results showed a significant, although small, effect of epidural corticosteroid injections compared with placebo for leg pain in the short term (mean difference, -6.2 [95% CI, -9.4 to -3.0]) and also for disability in the short term (mean difference, -3.1 [CI, -5.0 to -1.2]). The long-term pooled effects were smaller and not statistically significant.","claim_ids":[],"hash":"602eb960ca61ac3d1cf746ecba7af773e3e33478789a63ef745555fb2dc57d92"},{"id":"s24","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/16371894/","title":"The treatment of disc herniation-induced sciatica with infliximab: results of a randomized, controlled, 3-month follow-up study (Spine, 2005; PMID 16371894)","quote":"Forty patients were allocated to a single intravenous infusion of either infliximab 5 mg/kg or placebo. A significant reduction in leg pain was observed in both groups, with no significant difference between treatment regimens. Seven patients in each group required surgery.","claim_ids":[],"hash":"7b97ebab43e89d414cb7638f7e7ef767a02fbaa18b1e7a422a7f3d75c8beb8c3"},{"id":"s25","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/22508732/","title":"Epidural steroids, etanercept, or saline in subacute sciatica: a multicenter, randomized trial (Ann Intern Med, 2012; PMID 22508732)","quote":"The group that received epidural steroids had greater reductions in the primary outcome measure than those who received saline (mean difference, -1.26 [95% CI, -2.79 to 0.27]; P = 0.11) or etanercept (mean difference, -1.01 [CI, -2.60 to 0.58]; P = 0.21).","claim_ids":[],"hash":"a00d9be6293370fdc8ef57c1c2624c082eefd6637b80a46957b8933846c37982"},{"id":"s26","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/24165696/","title":"Randomized, double-blind, placebo-controlled trial of transforaminal epidural etanercept for symptomatic lumbar disc herniation (Spine, 2013; PMID 24165696)","quote":"Patients receiving 0.5-mg etanercept showed a clinically and statistically significant (P< 0.1) reduction in mean daily WLP compared with the placebo cohort from 2 to 26 weeks for both the per protocol population (-5.13 vs. -1.95; P= 0.066) and the intention-to-treat population (-4.40 vs. -1.84; P= 0.058).","claim_ids":[],"hash":"0faea4e3ffa31ae331eb290d552eb931b3cc34246d631c764239a32bb2f4ceba"},{"id":"s27","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/42542926/","title":"Effects of BPC-157 and TB-500 on Achilles tendon healing in rats (Jt Dis Relat Surg, 2026; PMID 42542926)","quote":"Combined BPC-157 and TB-500 treatment did not confer additional benefits compared to either agent alone. The absence of additive effects with combination therapy may reflect convergence on shared downstream pathways; however, this hypothesis requires further experimental confirmation.","claim_ids":[],"hash":"f74201790a170127d18ab8e4d7a9070db456caf7af4acceb79d6b59acf6fa883"},{"id":"s28","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/28475703/","title":"Cibinetide Improves Corneal Nerve Fiber Abundance in Patients With Sarcoidosis-Associated Small Nerve Fiber Loss and Neuropathic Pain (IOVS, 2017; PMID 28475703)","quote":"The placebo-corrected mean change from baseline CNFA (um2) at day 28 was 109 (95% confidence interval [CI], -429, 647), 697 (159, 1236; P = 0.012), and 431 (-130, 992) in the 1, 4, and 8 mg groups, respectively. Pain improved significantly in all groups, with subjects having moderate-severe pain reporting a clinically meaningful placebo-corrected decrease in pain intensity in the 4 mg group (P = 0.157).","claim_ids":[],"hash":"90dc1a0218b3019f29f6b6ab0d7e3c3a445e23bad7ea9dee7999b3f7e5c15d74"},{"id":"s29","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23168581/","title":"Safety and efficacy of ARA 290 in sarcoidosis patients with symptoms of small fiber neuropathy: a randomized, double-blind pilot study (Mol Med, 2012; PMID 23168581)","quote":"A total of 22 patients diagnosed with sarcoidosis and symptoms of SFN were enrolled in a double-blind, placebo-controlled exploratory trial. The ARA 290 group showed significant (p < 0.05) improvement at wk 4 in SFNSL score compared with placebo. The mean BPI and FAS scores improved significantly but equivalently in both patient groups.","claim_ids":[],"hash":"a0e8815fd61d935b0749fffab4e79d2bbb9c3db981870afecdac59d3e761c6c1"},{"id":"s30","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25430861/","title":"Systematic literature review of imaging features of spinal degeneration in asymptomatic populations (AJNR, 2015; PMID 25430861)","quote":"Disk protrusion prevalence increased from 29% of those 20 years of age to 43% of those 80 years of age. Imaging findings of spine degeneration are present in high proportions of asymptomatic individuals, increasing with age.","claim_ids":[],"hash":"e73e4bc39d8be90cc4267bd894484e68b30b3db51a5331534b3fa2dde8a6e9ea"},{"id":"s31","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/18777603/","title":"The cost effectiveness of surgical versus nonoperative treatment for lumbar disc herniation over two years: evidence from SPORT (Spine, 2008; PMID 18777603)","quote":"Surgery was more costly than nonoperative care; the mean difference in total cost was $14,137 (95% CI: $11,737-16,770). The cost per QALY gained for surgery relative to nonoperative care was $69,403 (95% CI: $49,523-94,999) using general adult surgery costs and $34,355 (95% CI: $20,419-52,512) using Medicare population surgery costs.","claim_ids":[],"hash":"2b20ce8eac9d6ca0e2d5b95e17f1c9694c8dc60a493cfadafa91ae1f09579b6e"},{"id":"s35","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/29284846/","title":"Comparison of the Intravenous and Epidural Administration of TNF-alpha Antagonists in an Experimental Rat Pain Model (Anesth Essays Res, 2017; PMID 29284846)","quote":"Inflammatory cytokines secreted from the nucleus pulposus are thought to lead to lumbar nerve root compression-like symptoms. Tumor necrosis factor-alpha (TNF-a), an inflammatory cytokine, likely plays an important role in lumbar disc hernia-related leg pain.","claim_ids":[],"hash":"e82a7ec43c2632ea92af8925155a0f143097e30a220cb704246f2f1f95e3988e"}],"user_reports":[],"related_articles":[{"slug":"bpc-157","title":"BPC-157: Body Protection Compound","claims":[{"id":"c1","text":"BPC-157 is a made-in-a-lab chain of 15 amino acids, copied from a stretch of a protein found in stomach juice.","tier":"human"},{"id":"c2","text":"More than 100 studies in animals and in cells report faster healing — better-organised collagen, and blood vessels growing into the wound — across tendon, gut, muscle, bone and nerve.","tier":"preclinical"},{"id":"c3","text":"A 2025 pilot study dripped up to 20 mg of BPC-157 into the veins of two healthy adults. Nothing went wrong with their vital signs, their blood tests, or how they said they felt.","tier":"human"},{"id":"c4","text":"The proposed explanation is that BPC-157 encourages new blood vessel growth at the injury and works on the body’s nitric oxide system. That is a proposal drawn from animal work, not something measured in a person.","tier":"mechanistic"},{"id":"c6","text":"One person reported feeling sick within two weeks of starting BPC-157 and stopped taking it. That is one person. The same account was then ingested 25 more times from other copies of the same thread, and each copy is listed below so the count is visible rather than hidden.","tier":"anecdotal"},{"id":"c8","text":"The second copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 2 people.","tier":"anecdotal"},{"id":"c10","text":"The third copy of that same single nausea report, ingested again from another copy of the same thread. It is the same one person, not 3 people.","tier":"anecdotal"},{"id":"c11","text":"Ten of the sources catalogued on this page are vendors and clinics selling BPC-157. That is marketing material, and it is listed here as marketing material rather than as evidence.","tier":"human"}]},{"slug":"tb-500","title":"TB-500: a seven-amino-acid fragment sold under the name of the protein thymosin beta-4","claims":[{"id":"c1","text":"TB-500 is sold as a made-in-a-lab version of thymosin beta-4, a small protein your own cells already make.","tier":"mechanistic"},{"id":"c300","text":"Thymosin beta-4 is the body's main handler of loose actin, the building material a cell uses to change shape and crawl.","tier":"mechanistic"},{"id":"c301","text":"Holding that building material is how thymosin beta-4 sets the pace at which cells move into an injury, and cells moving into an injury is what repair is.","tier":"mechanistic"},{"id":"c2","text":"The same seven amino acids that let thymosin beta-4 grip actin also make new blood vessels grow.","tier":"mechanistic"},{"id":"c302","text":"Those seven amino acids also make the cells that line blood vessels crawl, so new blood vessel growth is not a side effect of the repair. It is part of it.","tier":"mechanistic"},{"id":"c3","text":"In controlled animal wound experiments, thymosin beta-4 made skin grow back across the wound 42 to 61% faster than in untreated animals.","tier":"preclinical"},{"id":"c303","text":"Those same animal wounds laid down more collagen and grew more new blood vessels.","tier":"preclinical"},{"id":"c4","text":"Thymosin beta-4, the full protein rather than the fragment in the vial, was tested in people with pressure sores and long-standing leg ulcers in proper randomised, double-blind, placebo-controlled trials.","tier":"human"}]},{"slug":"ara-290","title":"ARA-290 (cibinetide): a fragment of erythropoietin that acts on nerves, not on blood","claims":[{"id":"c1","text":"ARA-290 (cibinetide) is an 11-amino-acid peptide from EPO's helix-B surface that activates the innate repair receptor (EPOR/beta-common heterocomplex) to drive tissue repair, distinct from EPO's erythropoietic receptor.","tier":"mechanistic"},{"id":"c2","text":"Because it engages the innate repair receptor rather than the homodimeric EPO receptor, ARA-290 does not stimulate erythropoiesis or raise hematocrit, avoiding EPO's thrombotic risk.","tier":"mechanistic"},{"id":"c3","text":"The mechanism was defined by Michael Brines and Anthony Cerami, who showed EPO's tissue protection runs through an EPOR/beta-common-receptor heterocomplex.","tier":"mechanistic"},{"id":"c4","text":"In a randomized, double-blind, placebo-controlled pilot in sarcoidosis patients with small-fiber neuropathy, ARA 290 significantly improved neuropathy symptom scores versus placebo.","tier":"human"},{"id":"c5","text":"In a Phase 2b RCT (n=64), 4 mg/day cibinetide significantly increased corneal nerve fiber area and raised GAP-43+ regenerating intraepidermal nerve fibers, an objective structural sign of nerve regeneration.","tier":"human"},{"id":"c6","text":"In type 2 diabetics, ARA 290 improved neuropathic symptoms alongside HbA1c and lipids over 56 days without safety issues.","tier":"human"},{"id":"c7","text":"In nerve-injury models, ARA 290 produced long-lasting, dose-dependent reductions in allodynia coupled to suppression of the spinal microglial neuroinflammatory response.","tier":"preclinical"},{"id":"c8","text":"ARA 290 inhibits macrophage activation and pro-inflammatory cytokine release (IL-6, IL-12, TNF-alpha) and protects cells from cytokine-induced apoptosis.","tier":"preclinical"}]},{"slug":"herniated-disc","title":"Herniated disc: 70% resorb without surgery and 95% recover at one year","claims":[{"id":"c1","text":"A herniated disc is not a broken part. Tissue has moved, that is all: the soft centre of the disc has pushed out through a tear in the tough outer ring.","tier":"mechanistic"},{"id":"c300","text":"The tear almost always sits towards the back and a little to one side, where the tough outer ring is thinnest. A nerve root runs right there, which is why the escaped material ends up pressing on it.","tier":"mechanistic"},{"id":"c2","text":"Most herniated discs shrink away on their own. Pooled data put it at roughly two-thirds of the people who were never operated on.","tier":"human"},{"id":"c3","text":"The biggest herniations are the ones that clear best. A piece squeezed right out through a tear, or one that has broken clean away, disappears completely far more often than a small bulge that never breached the outer ring.","tier":"human"},{"id":"c4","text":"The fragment does not simply dry up and vanish. Scavenger cells from your immune system, called macrophages, move in on the escaped material and eat it.","tier":"mechanistic"},{"id":"c301","text":"Those same scavenger cells set off enzymes and new blood vessel growth, and between them the fragment is dissolved and carried away.","tier":"mechanistic"},{"id":"c5","text":"Mature disc tissue has almost no blood supply of its own, which is why it heals so slowly.","tier":"mechanistic"},{"id":"c302","text":"Recovery depends on new blood vessels growing in at the edge of the herniation, pushed along by a signalling protein called VEGF, bringing a blood supply to a place that normally has none.","tier":"mechanistic"}]},{"slug":"degenerative-disc-disease","title":"Degenerative Disc Disease","claims":[{"id":"c1","text":"Degeneration starts as a failure to hold water. The soft centre of the disc loses aggrecan, the molecule that pins water in place, and the water leaves with it.","tier":"mechanistic"},{"id":"c320","text":"A disc is roughly 90% water at birth and around 70% by age 60. Once it is that dry it can no longer hold pressure and share the load the way it is supposed to.","tier":"mechanistic"},{"id":"c2","text":"The disc heals badly because it is the largest structure in the body with no blood supply of its own. Everything it needs seeps slowly in through the bony plates above and below it.","tier":"mechanistic"},{"id":"c3","text":"Once the centre has dried out, the load shifts onto the tough outer ring, which starts to crack and tear. The disc does try to repair itself, but the breaking down keeps running ahead of the repair.","tier":"mechanistic"},{"id":"c4","text":"Two inflammatory signals, TNF-alpha and IL-1beta, do most of the driving in disc degeneration and in pain that comes from the disc itself. The disc's own cells are what make them.","tier":"mechanistic"},{"id":"c321","text":"Those same two signals coax nerve fibres to grow into a disc that in health has no nerves inside it at all.","tier":"mechanistic"},{"id":"c5","text":"In a controlled rat study, injecting TNF-alpha produced both pain and degeneration, and blocking it at the moment of injury stopped both from appearing. That makes TNF-alpha a cause and not just a marker.","tier":"preclinical"},{"id":"c6","text":"TNF-alpha tips the disc's building-and-breaking balance towards breaking. It raises the enzymes that chew up the disc's scaffolding, called MMPs, faster than it raises the TIMPs that hold those enzymes back.","tier":"mechanistic"}]}],"question_graph":{"slug":"what-are-peptides-herniated-disc","questions":[],"evidence":[],"edges":[],"counts":{"questions":0,"evidence":0,"edges":0}},"honesty":{"active_claims":40,"retracted_claims":0,"cut_claims":0,"challenges":0,"scrub_events":0,"note":"Retracted/cut claims stay on ledger but are excluded from ask unless ?include_inactive=1"},"counts":{"claims":40,"claims_total":40,"sources":32,"anecdotal":6,"scientific":17,"user_reports":0,"questions":0,"evidence_ingests":0}}